alexa Radio-Active Iodine Ablation in Well-differentiated Thyroid Cancers | Open Access Journals
ISSN: 2155-9619
Journal of Nuclear Medicine & Radiation Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Radio-Active Iodine Ablation in Well-differentiated Thyroid Cancers

Russell N Moule*

Mount Vernon Cancer Centre, Northwood, Middlesex, HA6 2RN, UK

*Corresponding Author:
Russell N Moule
Mount Vernon Cancer Centre
Northwood, Middlesex, HA6 2RN, UK
E-mail: [email protected]

Received date: July 19, 2012; Accepted date: July 20, 2012; Published date: July 23, 2012

Citation: Moule RN (2012) Radio-Active Iodine Ablation in Well-differentiated Thyroid Cancers. J Nucl Med Radiat Ther 3:e103. doi:10.4172/2155-9619.1000e103

Copyright: © 2012 Moule RN. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Nuclear Medicine & Radiation Therapy

Well differentiated thyroid cancers are relatively rare and are 1% of all cancer diagnoses. The main stay of treatment is thyroidectomy (hemi- and completion), followed by radioactive-iodine abalation. Radio-active iodine (131I) ablation after thyroidectomy in patients with well-differentiated thyroid cancers (Papillary, Follicular, and Mixed) is common practice although the optimal administered dose has been debated.

The management of thyroid cancer has been formalised like other cancers. The Royal College of Physicians (UK) and the American Thyroid Association have both produced guidance.

Recurrence and survival has been quoted at both 10 and 20 years depending on risk factors and the prognostic system used. The most commonly used are the AJCC TNM (Tumour, Node Metastasis) staging, and MACIS (Metastasis, Age at presentation, Completeness of surgical resection, Invasion – extra-thyroidal, and Size). Others scoring systems include AMES (Age at presentation, Metastases, Extent, Size of primary tumour), AGES (Age or presentation, Grade of Histology, Extent, Size of primary) and those from the EORTC.

Poor prognostic factors include: male, age greater than 40, tumour size greater than 5cm, widely invasive cancers or those with vascular invasion or poor differentiation, the presence of lymph node involvement or metastatic disease at presentation.

The use of 131I ablation (3.7 GBq) aims to kill any remaining thyroid cells, as well as any potentially residual microscopic disease. The serum thyroglobulin (Tg) measurements post-treatment will be more sensitive as Tg may be produced by normal thyroid cells and thyroid cancer cells. The rationale therefore is that any rise in the Tg after 131I ablation (providing the patient is adequately TSH suppressed on thyroxine) is due to the presence of thyroid cancer cells rather than normal thyroid cells and suggestive of persistent or recurrent disease. Also ablation reduces the risk of recurrence and prolongs survival.

The absolute indications of 131I ablation include T3 disease (>4cm), extra-thyroidal extension or capsular extension, lymph node involvement (with or without extra-capsular spread) or the presence of metastatic disease. Others include age greater than 45 years, tumour size 1 to 1.5cm. Very low risk patients for example completely excised tumours less than 1cm in size will not require ablative treatment.

However in patients with lower risk disease the decision to proceed with 131I ablation is not as clear cut and the use of a lower dose of 131I ablation may suffice. Hackshaw, et al. in 2007 [1] undertook a systematic review into the success of low-dose 131I ablation (1.1 GBq equivalent to 30 mCi) compared to a standard 3.7 Gbq (100 mCi) ablative dose. Unfortunately the data did not provide any robust conclusions.

The HiLO study [2] has specifically tried to address this issue. This study compared 1.1 GBq and 3.7 GBq ablative doses as well as the use of recombinantTSH (rTSH). Patients with T1 to T3 N0/1 M0 well differentiated thyroid cancer as well as Hurthle cell cancer we randomised to 1.1 GBq and 3.7 GBq radio-active iodine ablation and either rTSH (0.9mg day 1 and 2 pre-radioactive iodine) or standard withdrawal of thyroxine or liothyronine.

Out of the 438 patients that were recruited to the study 421 patients were evaluated. There was no significant difference in the ablation success between the two doses of radioactive iodine (85.0% vs. 88.9%). This was also the case for the use of rTSH. Nine and a half percent of patients who received 1.1 GBq required a further re-treatment compared to 4.1% in the 3.7 GBq group (p=0.02) However there was a significant reduction in the number of days admission. Patients who received 1.1 GBq were more likely to spend less time in hospital with 39.6% compared to 7.1% requiring only one day admission (p<0.001). Less side effects were also experienced in the 1.1 GBq group (21% vs. 33% p<0.007).

This study has provided important information as there was no difference in the ablation success rate between the low dose and high dose groups and similarly the use of rTSH did not have a significant impact on this rate.

As far as quality of life is concerned the use of 1.1 GBq radio-active iodine abaltion has significant advantages as the radiation protection issues surrounding administration are less and patients spend less time isolated and away from family life. For units that have pressure on treatment room usage 1.1 GBq in this group of patients allows a greater throughput and less treatment delays.

Following this study the same group attempting to answer the next question of whether radio-active iodine ablation is actually required in low-risk patients. This is being addressed through the IoN (Iodine or Not in low risk differentiated thyroid cancer) study.

There is no disadvantage with the use of low dose 1.1 GBq radioactive iodine ablation compared to 3.7 GBq in patients with low risk well differentiated thyroid cancers. The HiLo [3] study is a great step forward in the management of the patients and IoN will provide further valuable information over the coming years.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 11596
  • [From(publication date):
    August-2012 - Sep 25, 2017]
  • Breakdown by view type
  • HTML page views : 7831
  • PDF downloads :3765
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords